Esperion Therapeutics CFO James Conway to Depart Effective June 30

ANN ARBOR, Mich., June 1, 2026 — Esperion Therapeutics Inc. reported that Chief Financial Officer James Conway will depart the company effective June 30, 2026.

The departure was disclosed in Item 5.02 of Form 8-K filed with the Securities and Exchange Commission on June 1. The filing does not state a reason for Conway’s exit or name an immediate successor.

Item 5.07 of the same filing also reports results of matters submitted to a vote of security holders at the company’s annual meeting, though specific vote tallies are contained in the exhibits referenced under Item 9.01.

Esperion Therapeutics, which develops and commercializes cholesterol-lowering therapies, must now navigate the operational transition of its finance function. Public companies are required to disclose principal officer departures within four business days and typically follow with a separate filing once a permanent or interim CFO is appointed.

Downstream, the company will face standard executive-compensation disclosure obligations for Conway’s separation arrangements in its next proxy statement or Form 10-K. Any interim appointment or permanent hire will require an additional 8-K within four business days of the decision.

Until a successor is named, the chief executive officer or another officer will assume responsibility for financial reporting, Sarbanes-Oxley certifications, and interactions with auditors and lenders.

This marks the latest senior-executive change at Esperion. The company has previously disclosed leadership adjustments tied to its commercial-stage operations and ongoing regulatory commitments with the Food and Drug Administration for its bempedoic acid franchise.

The filing consists of the Form 8-K, exhibit 99.1 (press release if issued), and any meeting materials required under Item 9.01.